Published in final edited form as:

J Org Chem. 2009 June 5; 74(11): 4195–4202. doi:10.1021/jo900666r.

Spiroborate Ester-Mediated Asymmetric Synthesis of β -Hydroxy Ethers and its Conversion to Highly Enantiopure β -Amino Ethers

Kun Huang, Margarita Ortiz-Marciales^{*}, Wildeliz Correa, Edgardo Pomales, and Xaira Y. López

Department of Chemistry, University of Puerto Rico-Humacao, CUH Station, Humacao, Puerto Rico 00791-4300, USA.

Abstract

Borane-mediated reduction of aryl and alkyl ketones with α -aryl- and α -pyridyloxy groups affords β -hydroxy ethers in high enantiomeric purity (up to 99% ee) and in good yield, using as catalyst 10 mol % of spiroborate ester **1** derived from (*S*)-diphenylprolinol. Representative β -hydroxy ethers are successfully converted to β -amino ethers, with minor epimerization, by phthalimide substitution under Mitsunobu's conditions followed by hydrazinolysis, to obtain primary amino ethers or by imide reduction with borane to afford β -2,3-dihydro-1*H*-isoindol ethers. Non-racemic Mexiletine and nAChR analogues with potential biological activity are also synthesized in excellent yield by mesylation of key β -hydroxy pyridylethers and substitution with 5, 6 and 7 member ring heterocyclic amines.

Introduction

Optically active β -hydroxy ethers are valuable building blocks in organic synthesis, in particular for their transformation to enantiopure β -amino ethers, which are important precursors in the preparation of a wide variety of pharmaceutical compounds.¹ Accordingly, various methods have been sought for the asymmetric synthesis of β -hydroxy ethers, such as, the enantioselective ring opening of epoxides catalyzed by chiral Salen complexes² and ring opening of optically active aryl oxiranes.^{1a} However, the steric and electronic factors controlling the regioselectivity of the nucleophilic ring opening, usually, can generate a mixture of products producing modest yields.³ Furthermore, the classic method of ring opening, usually, requires high temperature and longer reaction time associated with side reactions, such as, isomerization, epimerization and/or rearrangement.^{1a,4} Recently, Wills and co-workers⁵ studied the asymmetric transfer hydrogenation of functionalized acetophenone by a ruthenium

ortiz@quimica.uprh.edu.

Supporting Information Available: experimental data and full characterization of new and known compounds, and spectral and chromatographic data of starting materials and enantiopure compounds. This material is free of charge via the Internet at <http://pubs.acs.org>.

(II) catalyst with a tethering group attachment from the basic nitrogen atom to the arene ligand. They applied the method to the reduction of a ketone ether obtaining the corresponding β -hydroxy ether in 95% ee. The environmentally benign asymmetric reduction of functionalized ketones mediated by 1,3,2-oxazaborolidines (OB) and other chiral borane reagents has been extensively investigated by Corey⁶ and other groups (Figure 1).^{7,8} The *B*-H oxazaborolidine (**2a**) catalyzed reduction has been widely applied with high enantioselectivity and predictable configuration to α -haloketones,⁹ α -[(triorganosilyl)oxy] ketones,^{10a} α -(2-pyranil)oxy ketones,^{10b} α -sulfonyloxy ketones,^{10c} α -amido ketones,^{10d} diketones,¹¹ α -keto acetals,¹² α,β -enones and ynones,¹³ α -azido ketones,^{7h,j} ketone esters,^{7f} ketophosphonates,¹⁴ β -keto sulfides and sulfones.¹⁵ However, the in situ prepared *B*-H oxazaborolidines may possibly form side-products that can diminish the efficiency of the catalyst.¹⁶ Although *B*-Me and *B*-*n*-Bu oxazaborolidines (**2b**, **2c**) could overcome these disadvantages, the use of relatively expensive trialkylboroxine or alkylboronic acid and the careful purification procedure required for their preparation, make these reagents expensive for multigram syntheses. The enantioselective reduction of β -keto ethers using affordable and environmentally friendly chiral boron catalysts is expected to be one of the most convenient methods for the synthesis of optically active β -hydroxy ethers.

Recently, a series of air and moisture-stable crystalline spiroborate esters has been easily synthesized in our laboratory from non-racemic 1,2-amino-alcohols, ethylene glycol and inexpensive triisopropyl borate.^{17a–b} Spiroborate ester **1** (Figure 1) derived from diphenyl prolinol, which was isolated and characterized by X-ray, optical and spectroscopical methods, has demonstrated outstanding enantioselectivity for ketone reductions.^{17c–d} The facile and successful use of spiroborate ester **1**, has prompted us to investigate its application for the reduction of key β -keto ethers. Herein, we wish to report a highly efficient synthesis of β -hydroxy ethers with excellent enantiomeric purity in high yield and study its conversion to a wide variety of β -amino ethers, Mexiletine and nAChR analogues.

Results and Discussion

The reduction of ketone ether **6a**, as shown in Scheme 1, was initially selected as a model substrate. Ketone **6a** was readily prepared in high yield by the treatment of 2-bromoacetophenone with K_2CO_3 (1.5 equiv) and 2,6-dimethylphenol (1.5 equiv) in DMF at room temperature for 24 h.¹⁸ To establish the most advantageous conditions, different catalytic loads (Table 1, entry 1–3), dioxane as an alternative solvent and the use of other borane sources (entries 4–6), were evaluated. Initially, the reduction of ketone **6a** with $BH_3 \cdot DMS$ in THF at 25 °C using 1%, 5% and 10% of catalyst **1** was investigated. A remarkable increase in enantioselectivity and efficiency of the reaction was achieved with 10% of catalyst, providing the alcohol **7a** in 98% ee and 96% isolated yield. Dioxane was found as an unsuitable solvent for the reaction, giving only 65% ee. Although $BH_3 \cdot BACH$ -EI (Borane *N*-ethyl-*N*-isopropylaniline complex) and $BH_3 \cdot THF$ provided 99% and 98% ee, respectively, $BH_3 \cdot DMS$ was more attractive due to its low price and stability.

Having optimized the reaction conditions, the reduction of a variety of β -keto aryl and pyridyl ethers with aliphatic and aromatic substituents was accomplished. Table 2 illustrates the optical rotation, yield and enantiomeric excess for the prepared enantiopure secondary alcohols. In general, the β -hydroxy ethers were afforded in 92–99% ee and with excellent yield. Generally, steric and electronic effects of the substituents attached to both aromatic rings on the enantioselectivity of the reaction were not observed. For example, β -aryl keto ethers bearing both electron-withdrawing and electron-donating groups on the aryl groups afford excellent enantioselectivities (entries 1–7). It is important to note that the reduction of aliphatic β -keto ethers containing cyclohexanyl and adamantyl groups provide the desired alcohols in 93% ee and 99% ee, respectively, and in high yield (entries 8 and 9). It should be pointed out that 1.7

equiv $\text{BH}_3\cdot\text{DMS}$ is needed for the reduction of pyridyl ethers because one borane molecule coordinates to the pyridine nitrogen. Surprisingly, the β -keto 2-pyridyl ethers (entries 10, 11 and 13), that could bring forth a non-selective intramolecular borane reduction, afford excellent enantioselectivities in good to high yields. The 3-pyridyl ethers also offered high enantio-purity and excellent yields (entries 12–14). The absolute configuration of products was determined by comparison with the optical rotations of corresponding known compounds.^{1a}

Optically active β -amino aryl ethers display a key role in the treatment of neuromuscular disorders (Figure 2).¹ The commercial Mexiletine, as a racemate **8**, is used as an anti-arrhythmic and analgesic oral drug,^{1a} but due to side effects, such as dizziness, heartburn, nausea, nervousness, trembling and unsteadiness, its use is limited. The optically active Mexiletine analogue (*R*)-**9** is more potent than the more active (*R*)-Mexiletine isomer.^{1a,e} The racemic potent β -blocker of voltage-gated K^+ channels **10** was recently discovered, using structure-based virtual screening in combination with electrophysiological assays in rat hippocampal neurons.^{19f} In addition, other important β -amino ethers are neuronal nicotinic acetylcholine receptors (nAChRs) agonists, which are a group of ligand-gated ion channels that hold significant promise as therapeutic targets for the treatment of central nervous system (CNS) and peripheral nervous system disorders.²⁰ As shown in Figure 2, the β -amino pyridyl ethers A-84534 (**11**),²¹ ABT-594 (**12**),²² NIDA52189 (**13**)²³ and related compounds have been investigated as potential drug candidates. Recently, we reported a new methodology for the synthesis of novel Mexiletine analogues by the reduction of benzylated oxime ethers with excellent enantiopurity.^{18b} As part of our ongoing programs, we are interested in developing alternative methodologies for the synthesis of a variety primary β -amino pyridyl ethers with possible neurobiological activity. Since β -hydroxy ethers are easily converted into β -amino ethers employing the Mitsunobu reaction²⁴ with only slightly decrease in enantioselectivity,²⁵ we were interested in the synthesis of Mexiletine and nAChRs analogues from the previously prepared optically pure β -hydroxy pyridyl ethers.

As outlined in Table 3, the optically pure alcohols **7** were readily transformed into **14** by a stereo-specific substitution reaction of the hydroxyl group with phthalimide employing a typical Mitsunobu procedure. After hydrazinolysis of phthalimido ethers **14**, the desired bioactive β -amino ethers were obtained with inversion of configuration at the stereogenic center in moderate to good yields. Chiral HPLC analysis indicated high enantiomeric purity of the β -amino ethers **14** (95% ee to 99% ee) (Table 3 entries 1–6), with only a slight racemization. Interestingly, adamantyl and pyridyl ethers are also suitable substrates for this transformation demonstrating the efficiency and the functional tolerance of this reaction towards phenoxy and pyridyl groups.

Based upon similar structural features present in nAChRs agonist, we investigated the reduction of phthalimide ethers **14** to obtain 2,3-dihydro-1*H*-isoindol derivatives (Scheme 2). $\text{BH}_3\cdot\text{DMS}$ in THF (8 equiv) was employed for the imide reduction. After the mixture was refluxed for 1.5 h, the reaction was quenched with MeOH at 0 °C. As evidenced by TLC analysis, the starting material was consumed and only one compound was observed. Surprisingly, amide **16j**, formed by mono-reduction of the phthalimide ether, was identified by NMR analysis as the initial partial reduction product. After the reaction time was extended to 8 h, the target product **17j** was obtained in 71% yield.

Under the previous optimized conditions, representative substrates were reduced to 2,3-dihydro-1*H*-isoindol derivatives **17** using 8 equiv $\text{BH}_3\cdot\text{DMS}$ in anhydrous THF for 10 h. As shown in Table 4, various chiral 2,3-dihydro-1*H*-isoindol derivatives were provided in good to high yields. Moreover, by control of the reaction time, selective reduction can provide a rapid access to novel amides and amino acids with potential biological applications.

Many biologically important compounds contain an heterocyclic ring in their structure, and many piperidine derivatives are also in clinical and preclinical studies.²⁶ Our interest in the synthesis of nicotinic analogues prompted us to investigate the direct substitution of the hydroxyl group with a secondary cyclic amines, such as pyrrolidine, piperidine or azepane. Considering the efficiency and convenience of the Mitsunobu reaction, we initially explored this procedure (Figure 4). Unfortunately, no product was observed even by increasing the reaction temperature and time, and only starting materials were observed by TLC. Consequently, an alternative route was searched.

One of the most common methods for the preparation of tertiary heterocyclic amine is the displacement of a sulfonated intermediate with the secondary aliphatic amines. To investigate the possibility of this transformation with complete inversion of configuration, optically active alcohol **7a** (Table 5) was chosen as a model. The mesylate (*S*)-**18a** was prepared by conventional treatment of alcohol with mesyl chloride in the presence of Et₃N. Considering the instability of mesylate **18a** on the chromatographic column, this intermediate was used without further purification and was treated directly with pyrrolidine in acetonitrile. To our delight, the desirable product **19a** was obtained in 83% yield for the two steps. A baseline separation of the racemic sample was not satisfactory for chiral GC and HPLC analysis, however a good baseline separation was achieved for the chiral HPLC analysis of racemic compound **19b**. As indicated in table 5 (entry 3), the optical purity of this product was 98% ee. As desired, the reaction took place stereoselectively via an S_N2 process as the optical purity of **19b** is even higher than the enantiopurity of the starting alcohol (*S*)-**7l** (97% ee). Under similar condition, various secondary aliphatic amines and substrates were examined. As shown in Table 5, pyrrolidine, piperidine and azepane derivatives are obtained in good yields, providing a rapid access to new nicotinic acetylcholine receptors (nAChRs) analogues in high optical purity.

Conclusions

Spiroborate ester **1** demonstrated to be an excellent catalyst for the facile enantioselective borane reduction of representative β -keto aryl and pyridylethers using 10% of catalytic load in THF at room temperature. A wide range of aliphatic and aromatic β -hydroxy ethers were afforded in optically pure form in up to 99% ee and in high yield. Electronic factors or steric effects in the aryl or pyridyl rings, do not affect significantly the enantioselectivity of the spiroborate ester mediated reduction. The non-racemic β -hydroxy ethers were successfully converted to β -amino ethers with negligible epimerization by phthalimide substitution under Mitsunobu's conditions. By a facile imide hydrazinolysis, representative primary aryl and alkyl amino ethers were achieved in good yield. Complete phthalimide reduction with borane provided the corresponding β -2,3-dihydro-1*H*-isoindol derivatives in good yield. In addition, the partial imide reduction can afford important β -amide ethers, which by hydrolysis can be transformed to aromatic ortho-secondary amino acids with a β -aryl and pyridyloxy moiety. In addition, non-racemic novel Mexiletine and nAChR analogues with potential biological activity were synthesized in enantiopure form and excellent yields by mesylation of key β -hydroxy pyridylethers and in situ substitution with pyrrolidine, piperidine and azepane to form, respectively, 5, 6 and 7 member ring heterocyclic amino ethers.

Experimental Section

General Procedure for the Reduction of β -Keto Ethers (6a–6i)

To a dried 50 mL reaction tube under N₂, catalyst **1**^{17a} (65 mg, 0.2 mmol) and anhydrous THF (4 mL) was added. Then, BH₃·DMS (0.14 mL, 10.0 M) was added in one portion. The resulting mixture was stirred at room temperature for 30 min until a transparent solution was observed. A solution of β -keto ether¹⁸ (2 mmol) in THF (3 mL) was added dropwise during 1 h by a

syringe pump. The resulting mixture was stirred for another 1 h. Then, the reaction mixture was cooled with ice-bath and quenched with MeOH (3 mL). The solvents were removed under reduced pressure and to the residue was added 1N HCl (10 mL). The aqueous phase was extracted with ether (3×30 mL) and the combined organic phases were washed with brine and dried over Na₂SO₄. After solvent removal under reduced pressure and purification by silica gel column chromatography, the corresponding β -hydroxy ethers (**7**) were provided.

(S)-1-Adamantan-1-yl-2-phenoxy-ethanol (7i)—White solid; mp 65–66 °C; yield 96% (262 mg); >99% ee; $[\alpha]_D^{20} = +41$ (c 1.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 7–1.83 (m, 12H), 2.08 (m, 3H), 2.38 (br s, 1H, OH), 3.58 (m, 1H), 3.98 (m, 1H), 4.19 (m, 1H), 6.97–7.04 (m, 3H), 7.32–7.37 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 28.4, 35.7, 37.2, 38.4, 68.6, 114.7, 121.1, 129.5, 158.7; IR ν (cm⁻¹) 3454, 2912, 2893, 2848, 1600, 1585, 1497, 1450, 1298, 1241, 1172, 1086, 1048, 1034, 1022, 986, 895, 880, 814, 749, 688; ESI HRMS m/z calculated for C₁₈H₂₄NaO₂ (M+Na)⁺ 295.1674, found 295.1666. Enantiomeric excess was determined by HPLC with a Chiralpak OD-H column (95:5 hexane: 2-propanol), 0.5 mL/min, 254 nm, minor enantiomer t_R = 16.65 min, major enantiomer t_R = 26.69 min.

General Procedure for the Reduction of β -Keto Pyridyl Ethers (6j–6m)

To a dried 50 mL reaction tube under N₂, catalyst **1** (65 mg, 0.2 mmol) and anhydrous THF (4 mL) was added. Then, BH₃·DMS (0.34 mL, 10.0 M) was added in one portion. The resulting mixture was stirred at room temperature for 30 min until a transparent solution was observed. A solution of β -keto pyridyl ethers (2 mmol) in THF (4 mL) was added dropwise during 1 h by a syringe pump. The resulting mixture was stirred overnight. Then, the reaction mixture was cooled with ice-bath and quenched with MeOH (5 mL). After the mixture was refluxed for 3 hours, the solvents were removed under reduced pressure and the residue was purified by silica gel column chromatography.

(S)-2-(6-Chloro-pyridin-2-yloxy)-1-phenyl-ethanol (7j)—White solid; mp 85–86 °C; yield 88% (659 mg); 99% ee; $[\alpha]_D^{20} = +48$ (c 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 3.12 (br s, 1H), 4.41 (m, 1H), 4.60 (m, 1H), 5.19 (m, 1H), 6.78 (m, 1H), 6.98 (m, 1H), 7.35 (m, 1H), 7.44 (m, 2H), 7.53 (m, 2H), 7.62 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 72.2, 72.9, 109.4, 116.9, 126.3, 128.1, 128.6, 140, 141, 148.3, 163.2; IR ν (cm⁻¹) 3368, 2988, 2941, 1588, 1559, 1493, 1433, 1407, 1296, 1261, 1159, 1082, 1056, 1021, 1006, 983, 921, 899, 788, 756, 701; ESI HRMS m/z calculated for C₁₃H₁₂ClNNaO₂ (M+Na)⁺ 272.0454, found 272.0454. Enantiomeric excess was determined by HPLC with a Chiralpak OD-H column (9:1 hexane: 2-propanol), 0.5 mL/min, 254 nm, major enantiomer t_R = 16.72 min, minor enantiomer t_R = 20.54 min.

General Procedure for the Synthesis of Compounds **14** via a Mitsunobu Reaction

To a mixture of the optically pure alcohol (2 mmol), phthalimide (441 mg, 3 mmol) and triphenylphosphine (786 mg, 3 mmol) in 20 mL of anhydrous THF under N₂ at room temperature, a solution of DIAD (603 mg, 3 mmol) in anhydrous THF (10 mL) was added dropwise. The resulting mixture was stirred until TLC indicated that the alcohol was consumed. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography, affording the corresponding imide.

(R)-2-(1-Adamantan-1-yl-2-phenoxy-ethyl)-isoindole-1,3-dione (14i)—Colorless oil; yield 86% (345 mg); reaction time 72h; ¹H NMR (400 MHz, CDCl₃): δ 1.7–1.77 (m, 9H), 1.82–1.88 (m, 3H), 2.06 (m, 3H), 4.43 (m, 2H), 5.02 (m, 1H), 6.88 (m, 2H), 6.96 (m, 1H), 7.26 (m, 2H), 7.77 (m, 2H), 7.84 (m, 1H), 7.92 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 28.3, 28.4, 36.8, 37.1, 37.2, 38.4, 40.1, 60.8, 63.0, 115, 121, 123.1, 123.4, 129.4, 131.6, 133.8, 134.0, 158.6, 169.5; IR ν (cm⁻¹) 3512, 3039, 2900, 2847, 1773, 1710, 1599, 1587, 1496, 1450, 1392,

1345, 1241, 1171, 1076, 1032, 1013, 986, 874, 751, 736, 716, 690; ESI HRMS m/z calculated for $C_{26}H_{28}NO_3$ ($M+H$)⁺ 402.2069, found 402.2079.

General Procedure for the Synthesis of β -Amino Ether **15** via Hydrazinolysis

To a stirred solution of **14** (1 mmol) in 5 mL EtOH, 50–60% N_2H_4 (256 mg, 8 mmol) was added. The resulting mixture was refluxed for 3 h. The precipitated solid was filtered off and the solvent was removed under reduced pressure. The residue, dissolved in ether, was extracted with 2 N HCl and the aqueous phase was treated with 2 N NaOH until pH >12. The aqueous phase was extracted with ether (3×20 mL) and the combined organic phases were dried over Na_2SO_4 and evaporated under reduced pressure to give the target product. For the amine of **15i**, **15j** and **15l**, because of their water solubility, the desired products were obtained, directly, by silica gel column chromatography.

(R)-1-Adamantan-1-yl-2-phenoxy-ethylamine (15i)—White solid; mp 61–62 °C; yield 86% (465 mg); >99% ee; $[\alpha]_D^{20} = -29$ (c 1.0, $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$): δ 1.48 (bs, 2H), 1.72–1.81 (m, 12H), 2.07 (m, 3H), 2.78 (m, 1H), 3.82 (m, 1H), 4.22 (m, 1H), 4.50 (m, 1H), 6.96–7.01 (m, 2H), 7.31–7.35 (m, 2H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 28.5, 35.3, 37.3, 38.9, 59.5, 69.5, 114.7, 120.8, 129.5, 159.0; IR ν (cm^{-1}) 3371, 3308, 2901, 2893, 2849, 1727, 1599, 1587, 1498, 1467, 1449, 1301, 1285, 1243, 1179, 1077, 1038, 1031, 1018, 990, 960, 900, 879, 815, 755, 691; ESI HRMS m/z calculated for $C_{18}H_{26}NO$ ($M+H$)⁺ 272.2009, found 272.2015; Enantiomeric excess was determined by HPLC for acetyl derivative with a Chiralpak OD-H column (96:4 hexane: 2-propanol), 0.4 mL/min, 254 nm, major enantiomer t_R = 43.11 min, minor enantiomer t_R = 47.73 min.

(R)-2-(6-Methyl-pyridin-3-yloxy)-1-phenyl-ethylamine (15l)—Colorless oil; yield 66% (136 mg); 97% ee; $[\alpha]_D^{20} = -37$ (c 1.3, $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$): δ 1.98 (br s, 2H), 2.52 (s, 3H), 3.98 (m, 1H), 4.13 (m, 1H), 4.47 (m, 1H), 7.07–7.15 (m, 2H), 7.33–7.50 (m, 5H), 8.23 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 23.4, 55.2, 74.5, 122.1, 123.3, 126.9, 127.9, 128.7, 136.9, 141.6, 150.8, 152.9; IR ν (cm^{-1}) 3368, 3291, 3060, 3026, 2923, 2866, 1599, 1572, 1484, 1454, 1387, 1287, 1265, 1240, 1212, 1122, 1023, 825, 759, 702; ESI HRMS m/z calculated for $C_{14}H_{17}N_2O$ ($M+H$)⁺ 229.1341, found 229.1351; Enantiomeric excess was determined by HPLC for acetyl derivative with a Chiralcel OD-H column (9:1 hexane: 2-propanol), 0.5 mL/min, 254 nm, major enantiomer t_R = 46.32 min, minor enantiomer t_R = 55.8 min.

General Procedure for the Synthesis of Compounds **16** and **17** via Borane Reduction

To a stirred solution of **14** (1 mmol) in anhydrous THF under nitrogen, $BH_3 \cdot DMS$ (0.8 mL, 10 M, 8 mmol) was added. Compound **16** was produced after the mixture was refluxed for 1.5 h. Compound **17** was formed by complete reduction when the mixture was refluxed overnight. In both cases, the reaction mixtures were slowly quenched with 5 mL MeOH at 0 °C. The corresponding products were isolated after the solvents were evaporated under reduced pressure and the residue purified by silica gel column chromatography.

(R)-2-(1-Adamantan-1-yl-2-phenoxy-ethyl)-2,3-dihydro-isoindol-1-one (16i)—White solid; mp 148–150 °C; yield 81% (313 mg); 1H NMR (400 MHz, $CDCl_3$): δ 1.70–1.82 (m, 9H), 1.88 (m, 3H), 2.09 (m, 3H), 4.37 (m, 2H), 4.58 (m, 3H), 6.89–7.0 (m, 3H), 7.29 (m, 2H), 7.45–7.60 (m, 3H), 7.95 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 28.5, 36.9, 40.3, 64.5, 114.8, 121.1, 122.5, 123.9, 127.9, 129.5, 131.2, 141.6, 158.6; IR ν (cm^{-1}) 3039, 2918, 2899, 2875, 2850, 1731, 1676, 1597, 1498, 1483, 1448, 1401, 1303, 1288, 1246, 1218, 1175, 1164, 1018, 989, 947, 896, 879, 834, 815, 796, 753, 735, 688; ESI HRMS m/z calculated for $C_{26}H_{30}NO_2$ ($M+H$)⁺ 388.2277, found 388.2299.

(R)-2(1-Adamantan-1-yl-2-phenoxy-ethyl)-2,3-dihydro-1H-isoindole (17i)—

Colorless oil; yield 65% (121 mg); ^1H NMR (400 MHz, CDCl_3): δ 1.72–1.77 (m, 9H), 1.88 (m, 3H), 2.06 (m, 3H), 2.89 (m, 1H), 4.36 (m, 6H), 6.89–6.99 (m, 3H), 7.21 (m, 4H), 7.30 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 28.7, 37.3, 38.2, 40.2, 57.7, 64.9, 67.7, 114.6, 120.6, 122.1, 126.2, 129.4, 140.6, 158.8; IR ν (cm^{-1}) 2961, 2899, 2846, 1693, 1598, 1587, 1495, 1468, 1448, 1360, 1344, 1300, 1258, 1240, 1170, 1152, 1135, 1077, 1031, 1017, 858, 796, 739, 689; ESI HRMS m/z calculated for $\text{C}_{26}\text{H}_{32}\text{NO}$ ($\text{M}+\text{H}$) $^+$ 374.2484, found 374.2491.

General Procedure for the Synthesis of 18

To a two-neck round bottom flask under nitrogen, a solution of the nonracemic alcohol (2 mmol) in anhydrous CH_2Cl_2 (20 mL) and Et_3N (1.7 mL, 10 mmol) was added. The mixture was cooled to 0 °C and MsCl (0.46 mL, 6 mmol) was added dropwise for 0.5 h by a syringe pump. The resulting solution was stirred until TLC indicated that the starting material was consumed (about 30 min). Water (20 mL) was added to quench the reaction and the aqueous phase was extracted with CH_2Cl_2 (3×10 mL). The combined organic phases were washed with brine, dried over MgSO_4 and concentrated under reduced pressure at 25 °C, affording the crude product.

General Procedure for the Synthesis of 19

To the crude sulfonate intermediate **18** (2 mmol) in 10 mL CH_3CN at room temperature, the corresponding heterocyclic amine (5 equiv) was added. The resulting mixture was stirred overnight. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography.

(R)-2-Methyl-5-(2-phenyl-2-piperidin-1-yl-ethoxy)-pyridine (19b)—Colorless oil; yield 87% (259 mg); 98% ee; $[\alpha]_{\text{D}}^{20} = -13$ (c 1.3, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 1.45 (m, 2H), 1.62 (m, 4H), 2.52 (m, 7H), 3.80 (m, 1H), 4.32 (m, 1H), 4.42 (m, 1H), 7.05–7.13 (m, 2H), 7.33–7.40 (m, 5H), 8.2 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 23.4, 24.5, 26.3, 52.2, 69.2, 70.4, 122.4, 123.3, 127.5, 128.3, 128.5, 137.2, 150.5, 152.9; IR ν (cm^{-1}) 3374, 3059, 3028, 2931, 2853, 2799, 2755, 1600, 1572, 1485, 1471, 1452, 1387, 1266, 1239, 1212, 1175, 1118, 1027, 992, 912, 827, 758, 723, 699; ESI HRMS m/z calculated for $\text{C}_{19}\text{H}_{25}\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 297.1967, found 297.1968. Enantiomeric excess was determined by HPLC with a Chiralcel AD-H column (95:5 hexane: 2-propanol), 0.5 mL/min, 254 nm, major enantiomer $t_{\text{R}} = 17.65$ min, minor enantiomer $t_{\text{R}} = 19.62$ min.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank NIH for the financial support through their MBRS (GM 08216), INBRE (NC P20 RR-016470) and NSF-ADVANCE (SBE-0123645). Support for undergraduate scholars from the NIH-INBRE, NIH-RISE, NIH-MARC, and NSF-AMP programs is also gratefully acknowledged.

References

- (a) Franchini C, Carocci A, Catalano AA, Cavalluzzi MM, Corbo F, Lentini G, Scilimati A, Scilimati A, Tortorella P, Camerino DC, Luca A. J. Med. Chem 2003;46:5238. [PubMed: 14613326] (b) Wright JT, Gregory TF, Heffner TG, Mackenzie RG, Pugsley TA, Meulen SV, Wise LD. Bioorg. Med. Chem. Lett 1997;1377. (c) Baker NR, Byrne NR, Byrne NG, Economide AP, Javeld T. Chem. Phar. Bull 1995;1045. (d) Kirkup MP, Rizvi R, Shankar BB, Duggar S, Clader J, McCombie SW, Lin S, Yumibe N, Huie K, Heek M, Compton DS, Davis HR, Mcphail AT. Bioorg. Med. Chem. Lett 1996;2069. (e)

- Cavalluzzia MM, Catalano A, Bruno C, Lovecea A, Caroccia A, Corboa F, Franchinia C, Lentini G, Tortorella V. *Tetrahedron: Asymmetry* 2007;18:2409.
2. (a) Ready JM, Jacobsen EN. *J. Am. Chem. Soc* 1999;121:6086. (b) Ready JM, Jacobsen EN. *J. Am. Chem. Soc* 2001;123:2687. [PubMed: 11456948]
3. Guy A, Dubuffet T, Doussot J, God Froy-Falguieres A. *Synlett* 1991:403.
4. (a) Fringuelli F, Pizzo F, Vittorini C, Vaccaro L. *Chem. Commun* 2004:2756. (b) Kleiner CM, Schreiner PR. *Chem. Commun* 2006:4315. (c) Chem J, Shum W. *Tetrahedron Lett* 1995;36:2379–2382. (d) Fan RH, Hou XL. *J. Org. Chem* 2003;68:726. [PubMed: 12558391]
5. Morris DJ, Hayes AM, Wills M. *J. Org. Chem* 2006;71:7035. [PubMed: 16930059]
6. (a) Corey EJ, Bakshi RK, Shibata S, Chen CP, Singh VK. *J. Am. Chem. Soc* 1987;109:7925. (b) Corey EJ, Helal CJ. *Angew. Chem. Int. Ed* 1998;37:1986–2012. and references cited herein. (c) Sing VK. *Synthesis* 1992:605.(b)
7. (a) Wallbaum S, Martens J. *Tetrahedron: Asymmetry* 1992;12:1475–1504. (b) Kanth JVB, Brown HC. *Tetrahedron* 2002;58:1069. (c) Liu D, Shan Z, Zhou Y, Wu X, Qin. *J. Helv. Chim. Acta* 2004;87:2310. (d) Shan Z, Zhou Y, Liu D, Ha W. *Synth. React. Inorg. Met.Org. Nano-Met. Chem* 2005;35:275. (e) Yang S-D, Shi Y, Sun Z-H, Zhao Y-B, Liang Y-M. *Tetrahedron: Asymmetry* 2006;17:1895. (f) Wang G, Hu J, Zhao G. *Tetrahedron: Asymmetry* 2004;15:807. (g) Gamble MP, Studle JR, Wills M. *Tetrahedron Lett* 1992;37:2853. (h) Reddy MS, Narender Rao MKR. *Tetrahedron* 2007;63:331. (i) Eagon S, Kim J, Yan K, Haddenham D, Singaram B. *Tetrahedron Lett* 2007;48:9025. (j) Bolm C, Felder M. *Tetrahedron Lett* 1993;34:6041. (k) Bolm C, Seger A, Felder M. *Tetrahedron Lett* 1993;34:8079. (l) Yadav JS, Reddy PT, Hashim SR. *Synlett* 2000:1049. (m) Hu J, Zhao G, Yang G, Ding Z. *J. Org. Chem* 2001;66:303. [PubMed: 11429915]
8. (a) Cho BT. *Tetrahedron* 2006;62:7621. (b) Cho BT. *Chem. Soc. Rev* 2009;38:443. [PubMed: 19169459] (c) Cho BT. *Aldrichimica Acta* 2002;35:3.
9. (a) Hett R, Senanayake CH, Wald SA. *Tetrahedron Lett* 1998;39:1705. (b) Hett R, Fang QK, Gao Y, Wald SA, Senanayake CH. *Org. Process Res. Dev* 1998;2:96. (c) Wilkinson HS, Tanoury GJ, Wald SA, Senanayake CH. *Org. Process Res. Dev* 2002;6:146.
10. (a) Cho BT, Chun YS. *J. Org. Chem* 1998;63:5280. (b) Cho BT, Chun YS. *Tetrahedron: Asymmetry* 1999;10:1843. (c) Cho BT, Yang WK, Choi OK. *J. Chem. Soc. Perkin 1* 2001:1204. (d) Cho BT, Shin SH. *Bull. Korean Chem. Soc* 2004;25:747.
11. Prasad KKR, Joshi NN. *J. Org. Chem* 1996;61:3888. [PubMed: 11667247]
12. Cho BT, Chun YS. *J. Chem. Soc., Perkin Trans. 1* 1999:2095.
13. (a) Corey EJ, Helal CJ. *Tetrahedron Lett* 1995;36:9153–9156. (b) Parker KA, Ledebor MW. *J. Org. Chem* 1996;61:3214. [PubMed: 11667191]
14. Meier C, Laux WHG. *Tetrahedron: Asymmetry* 1995;6:1089.
15. (a) Cho BT, Choi OK, Kim DJ. *Tetrahedron: Asymmetry* 2002;13:697. (b) Cho BT, Shin SH. *Tetrahedron* 2005;61:6959. (c) Cho BT, Kim DJ. *Tetrahedron: Asymmetry* 2001;12:2043.
16. (a) Lang A, Noth H, Schmidt M. *Chem. Ber* 1997;130:241. (b) Mathre DJ, Thompson AS, Douglas AW, Carroll JD, Corley EG, Grabowski EJJ. *J. Org. Chem* 1993;58:2880. (c) Tlahuext H, Santiesteban F, García-Báez E, Contreras R. *Tetrahedron: Asymmetry* 1994;5:1579. (d) Santiesteban F, Mancilla T, Kláebe A, Contreras R. *Tetrahedron Lett* 1983;24:759. (g) Brown JM, Guy C, Lloyd-Jones GC, Layzell TP. *Tetrahedron: Asymmetry* 1993;4:2151. (e) Stepanenko V, Ortiz-Marciales M, Barnes CE, Garcia C. *Tetrahedron Lett* 2006;47:7603. (b) Ortiz-Marciales M, De Jesus M, Gonzales E, Raptis RG, Baran P. *Acta Crystallogr* 2004;C60:173.
17. (a) Stepanenko V, Ortiz-Marciales M, Correa W, De Jesús M, Espinosa S, Ortiz L. *Tetrahedron: Asymmetry* 2006;17:112. (b) Ortiz-Marciales, M.; Stepanenko, V.; Correa, W.; De Jesús, M.; Espinosa, S. U.S. Patent Application. 11/512,599. 2006 Aug 30. (c) Stepanenko V, De Jesús M, Correa W, Vázquez C, Guzman I, Vazquez C, De la Cruz W, Ortiz-Marciales M, Barnes CL. *Tetrahedron Lett* 2007;48:5799. [PubMed: 19554205] (d) Stepanenko V, Ortiz-Marciales M, De Jesús M, Correa W, Vázquez C, Ortiz L, Guzmán I, De la Cruz W. *Tetrahedron: Asymmetry* 2007;18:2738.
18. (a) Huang K, Ortiz-Marciales M, Merced FG, Meléndez HJ, De Jesús M, Correa W. *J. Org. Chem* 2008;73:4017. [PubMed: 18447392] (b) Huang K, Ortiz-Marciales M, Stepanenko V, De Jesús M, Correa W. *J. Org. Chem* 2008;73:6928. [PubMed: 18690744]

19. (a) De Luca A, Natuzzi F, Desaphy J-F, Loni G, Lentini G, Franchini C, Tortorella V, Conte Camerino D. *Mol. Pharmacol* 2000;57:268. [PubMed: 10648636] (b) De Luca A, Natuzzi F, Duranti A, Lentini G, Franchini C, Tortorella V, Conte Camerino D. *Naunyn-Schmiedeberg's Arch. Pharmacol* 1997;356:777. (c) De Luca A, Pierno S, Natuzzi F, Franchini C, Duranti A, Lentini G, Tortorella V, Jockush H, Conte Camerino D. *J. Pharmacol. Exp. Ther* 1997;282:93. [PubMed: 9223544] (d) Cannon SC. *Trends Neurosci* 1996;19:3. [PubMed: 8787138] (e) Lehmann-Horn F, Rüdel R. *Rev. Physiol. Biochem. Pharmacol* 1996;128:195. [PubMed: 8791722] (f) Liu H, Gao ZB, Yao Z, Zheng S, Li Y, Zhu W, Tan X, Luo X, Shen J, Chen K, Hu GY, Jiang H. *J. Med. Chem* 2007;50:83–93. [PubMed: 17201412]
20. (a) Karlin A. *Nat. Rev. Neurosci* 2002;3:102. [PubMed: 11836518] (b) Lloyd GK, Williams M. J. *Pharmacol. Exp. Ther* 2000;292:461. [PubMed: 10640281] (c) Tonder JE, Olesen PH. *Current Med. Chem* 2001;8:651. (d) Jensen AA, Frolund B, Liljefors T, Krosgaard- Larsen P. *J. Med. Chem* 2005;48:4705. [PubMed: 16033252]
21. Tonder JE, Olesen PH. *Curr. Med. Chem* 2001;8:651. [PubMed: 11281847]
22. (a) Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD, Williams M, Arneric SP. *Science* 1998;279:77. [PubMed: 9417028] (b) Holladay MW, Wasicak JT, He Y, Ryther KB, Bannon AW, Buckley MJ, Kim DB, Decker MW, Anderson DJ, Campbell JE, Kuntzweiler TA, Donnelly-Roberts DL, Piattoni-Kaplan M, Briggs CA, Williams M, Arneric SP. *J. Med. Chem* 1998;41:407. [PubMed: 9484491] (c) Abreo MA, Lin N-H, Garvey DS, Gunn DE, Hettinger A-M, Wasicak JT, Pavlik PA, Martin YC, Donnelly-Roberts DL, Anderson DJ, Sullivan JP, Williams M, Arneric SP, Holladay MW. *J. Med. Chem* 1996;39:817. [PubMed: 8632405]
23. Gao Y, Horti AG, Kuwabara H, Ravert HT, Hilton J, Holt DP, Kumar A, Alexander M, Enres CJ, Wong DF, Dannals RF. *J. Med. Chem* 2007;50:3814. [PubMed: 17629263]
24. Mitsunobu O. *Synthesis* 1981:1.
25. (a) Thompson AS, Humphrey GR, DeMarco AM, Mathre DJ, Grabowski EJJ. *J. Org. Chem* 1993;58:5886. (b) Chen C-P, Prasad K, Repic O. *Tetrahedron Lett* 1991;32:7175.
26. Watson PS, Jiang B, Scott B. *Org. Lett* 2000;2:3679. [PubMed: 11073674]

Figure 1. Spiroborate Ester **1**, Corey's Oxazaborolidines **2**, Brown's reagent **3**, Zhao's reagent **4** and TarB-X Singaram's reagent **5**.

FIGURE 2.
Mexiletine and Neuronal Nicotinic Acetylcholine Receptors Agonist

SCHEME 1.
Asymmetric Synthesis of Model β -hydroxy ether **7a**

SCHEME 2.
Reduction of Representative Phthalimide **14j**.

SCHEME 3.

Attempted Substitution of the Hydroxyl Group with Pyrrolidine by Mitsunobu's Method.

TABLE 1

Optimization Studies for the Asymmetric Reduction of β -Keto Ether **6a**^a

entry	borane	cat 1 (equiv)	solvent	yield (%) ^b	ee (%) ^c
1	BH ₃ ·DMS	0.01	THF	71	23
2	BH ₃ ·DMS	0.05	THF	83	66
3	BH ₃ ·DMS	0.1	THF	96	98
4	BH ₃ ·DMS	0.1	dioxane	96	65
5	BH ₃ ·BACH	0.1	THF	67	99
6	BH ₃ ·THF	0.1	THF	91	98

^a Unless otherwise stated, reactions were performed on a 2 mmol scale; 1 equiv ketone, 0.7 equiv BH₃ in THF at 25 °C for 1 h.

^b Purified by flash column chromatography.

^c Determined by chiral HPLC (Chiralcel OD-H column).

β -hydroxy ethers **7**

$[\alpha]_D^{20}$	<i>b</i>	yield (%)	<i>ee</i> (%)	entry
+17 (1.9)	96	98		8
+12 (1.2)	93	93		

+12 (1.2) 93 93

+17 (1.9) 96 98 **8**

J Org Chem. Author manuscript; available in PMC 2010 June 5.

$[\alpha]_D^{20}$	<i>b</i>	yield (%)	<i>ee</i> (%)	<i>c</i>	<i>d</i>
β-hydroxy ethers 7
+48 (1.0)	88 ^f	99
+24 (1.6)	95	98
+43 (1.2)	96	98
+43 (1.6)	94	98			

$ \begin{array}{c} \text{O} \\ \parallel \\ \text{R}-\text{C}-\text{CH}_2-\text{OAr} \\ \text{6} \end{array} \xrightarrow[\text{BH}_3\cdot\text{DMS}/\text{THF}/25^\circ\text{C}]{10\%\text{ Cat 1}} \begin{array}{c} \text{OH} \\ \mid \\ \text{R}-\text{CH}_2-\text{CH}_2-\text{OAr} \\ \text{7} \end{array} $	$ \begin{array}{c} [\alpha]_D^{20} \quad b \quad \text{yield} \quad ee \\ (\%)^c (\%)^d \end{array} $
	$ \begin{array}{c} +41 \quad (1.8) \quad 92 \quad 99 \quad \text{14} \end{array} $

TABLE 3

alcohols

	Phthalimide 14 yield (%) ^a	β -amino ether 15 yield <i>ee</i> (%) ^a (%) ^b
	79	85 96 ^c

Phthalimide 14 yield (%) ^a	β-amino ether 15	yield ee (%) ^d (%) ^b
84		88 98 ^c
77		62 95

yield *ee*
(%)^a(%)^b

β-amino ether **15**

Phthalimide **14**
yield (%)^a

85 97

86

Phthalimide 14
yield (%)^a

β -amino ether 15

yield *ee*
(%)^d(%)^b

90

66 97^c

TABLE 4

Synthesis of Novel nAChRs Analogues by Reduction of Optically Active Lactame **14**

entry	substrate 14
1

entry

substrate 14

2

entry

substrate 14

3

entry

substrate 14

4

entry

substrate 14

5

^aPurified by column chromatography on silica gel.

TABLE 5

Synthesis of β -Novel Heterocyclic Ethers

entry	product 19	$[\alpha]_D^{20}$ ^a yield (%) ^b
1	<p>a</p>	-15 (1.7) 83
2	<p>b</p>	-13 (1.2) 87 (98) ^c
3	<p>c</p>	+5 (2.1) 85

entry	product 19	$[\alpha]_{\text{D}}^{20}$ ^a	yield (%) ^b
4	<p style="text-align: center;">d</p>	-7 (1.4)	91
5	<p style="text-align: center;">e</p>	+6 (1.1)	86

^a CHCl₃ as solvent.

^b Purified by flash chromatography column.

^c Determined by chiral HPLC (Chiralcel AD-H column).